StockNews.com started coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Free Report) in a research note released on Monday morning. The firm issued a sell rating on the stock. A number of other brokerages have also issued reports on MBRX. Maxim Group dropped their price target on shares of Moleculin Biotech from $45.00 to $20.00 […]